The ASPH small molecule inhibitor 1182 (SMI1182) was shown to inhibit ASPH’s functions linked to Notch activation [36,48,49] and produce anti-tumor effects in experimental models of cholangiocarcinoma [48], hepatocellular carcinoma [38], pancreatic carcinoma [35], breast cancer [27], glioblastoma [36], and more recently, chondrosarcoma [40]. The gene discussed is ASPH; the disease is cholangiocarcinoma.